ClinicalTrials.gg
CompletedNCT02089685Updated Sep 13, 2022Results posted

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

A Phase 1/2 interventional study of Pembrolizumab and PegIFN-2b in Renal Cell Carcinoma and Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing pembrolizumab in Carcinoma, Renal Cell — 17 open to participants now, 23 under way, 4 of them phase 3. pembrolizumab · Carcinoma, Renal Cell.

Enrollment
8th of 48
295 · median 41
Started
2014
with 2 others
Phase 1/2
3 of 48
none open now
Registered
2nd of 48
by date
Lead sponsor
7 of 48
Merck Sharp & Dohme LLC

Among the 48 studies testing pembrolizumab in Carcinoma, Renal Cell, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 3 in phase 1/2, and was the 2nd registered.

Carcinoma, Renal Cell

2,041 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

17 of the 48 studies testing pembrolizumab in Carcinoma, Renal Cell are open now, in 8 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing pembrolizumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab + ipilimumab (IPI). The primary hypothesis is that these combinations will be sufficiently well-tolerated to permit continued clinical investigation.

Read the detailed description

The trial is being done in three parts: Part 1A (MEL and RCC) will define the maximum tolerated dose (MTD)/maximum administered dose (MAD) for the drug combinations; a recommended Phase 2 dose (RP2D) for each combination will be identified. Part 1B (MEL-single arm expansion) will better characterize safety and efficacy and provide preliminary efficacy data for the pembrolizumab + IPI combination in participants with MEL. Part 1C (MEL) is added as the third part of the study with Amendment 3. Part 1C will evaluate safety and efficacy for different doses and dosing intervals for IPI in combination with pembrolizumab in participants with advanced MEL.

In the pembrolizumab + IPI study arms, qualified participants who receive the first course but experience disease progression after discontinuing pembrolizumab with stable disease or better, may, at the investigator's discretion, initiate a second course of pembrolizumab at the same dose and schedule for up to 17 doses (up to \~1 additional year) + IPI at the same dose and schedule for up to 4 doses (up to \~12 additional weeks). In the pembrolizumab + PEG-IFN study arms, qualified participants who receive the first course but experience disease progression after discontinuing pembrolizumab with stable disease or better may, at the investigator's discretion, initiate a second course of pembrolizumab at the same dose and schedule for up to 17 doses (up to \~1 additional year). Per protocol, response or progression during the second course will not count towards efficacy outcome measure and adverse events during the second course will not count towards safety outcome measures.

Part 2 (MEL and RCC) is a randomized portion of the trial and will evaluate preliminary efficacy of the drug combinations for advanced MEL participants. Part 2 was removed from the study with Amendment 3 of the protocol.

03

Conditions studied

  • Renal Cell Carcinoma
  • Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-confirmed diagnosis of advanced/unresectable or MEL or RCC (Part 1A only) with predominantly clear cell elements
  • Previously untreated stage III/IV advanced or metastatic MEL (Part 1C only)
  • MEL subjects may be treatment naïve or may have received for metastatic disease (Parts 1A and 1B)
  • RCC subjects must have received ≥1 prior line of therapy for metastatic disease (Part 1A)
  • as defined by 1.1
  • Must provide a tumor sample (archival or newly obtained ) that is adequate for determination of PD (programmed cell death)-Ligand 1 status by immunohistochemistry at a central pathology laboratory prior to enrollment. Note: Adequacy of the tumor sample for PD-Ligand 1 testing is not required prior to enrollment in Part 1C
  • (ECOG) Performance Status of 0 or 1
  • Adequate organ function
  • Resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (Parts 1A and 1B) and/or recovered from major surgery or radiation therapy
  • Female participants of must be willing to use adequate during the course of the study through 120 days after the last dose of study drug
  • Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study drug

Exclusion criteria

Exclusion Criteria

  • Uveal or ocular MEL
  • Prior therapy with an anti-programmed cell death (anti-PD)-1, anti-PD-Ligand 1, anti-PD-Ligand 2 or with an agent directed to another co-inhibitory T-cell receptor or has previously participated in a pembrolizumab clinical trial. Note: In Part 1C, participants may have received and/or anti-Cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4) as part of their neo/ treatment.
  • Has received prior anti-cancer therapy, monoclonal antibody, chemotherapy, or an agent or device within 4 weeks or 5 half-lives (whichever is longer) before first dose of trial drug or not recovered (≤ Grade 1 or at baseline) from AEs due to previously administered agents (Parts 1A and 1B)
  • Diagnosis of immunodeficiency or is receiving chronic systemic therapy (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug
  • Known additional that is progressing or requires active treatment with the exception of early stage cancers (carcinoma in situ or Stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer or in situ breast cancer that has undergone potentially curative therapy
  • Known active central nervous system (CNS) and/or carcinomatous meningitis
  • Severe to any pembrolizumab
  • Active disease requiring systemic treatment in the past 2 years
  • History of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Active infection requiring systemic therapy
  • Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial from screening through 120 days after the last dose of study drug
  • Prior therapy with interferon alfa (in neoadjuvant, adjuvant, or metastatic settings) (Part 1A only)
  • Uncontrolled thyroid dysfunction
  • Uncontrolled diabetes mellitus.
  • Known history of (HIV)
  • Known history of or is positive for or
  • Received a within 30 days prior to first dose of study drug
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
295 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + PegIFN-2b

    Participants in Part 1A receive pembrolizumab intravenously (IV) 200 mg every three weeks (Q3W) + PEG-IFN at assigned dose subcutaneously (SC) once a week for up to \~2 years.

    Biological: Pembrolizumab · Biological: PegIFN-2b

  • Experimental
    Pembrolizumab + IPI Q3W

    Participants in Parts 1A and 1B receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 1 mg/kg Q3W for up to \~12 weeks.

    Biological: Pembrolizumab · Biological: Ipilimumab

  • Experimental
    Pembrolizumab + IPI Q6W

    Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 50 mg every 6 weeks (Q6W) for up to \~24 weeks.

    Biological: Pembrolizumab · Biological: Ipilimumab

  • Experimental
    Pembrolizumab + IPI Q12W

    Participants in Part 1C receive pembrolizumab IV 200 mg Q3W for up to \~2 years + IPI IV 100 mg every 12 weeks (Q12W) for up to \~48 weeks.

    Biological: Pembrolizumab · Biological: Ipilimumab

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: KEYTRUDA®, MK-3475

  • BiologicalPegIFN-2b

    Subcutaneous infusion

    Also known as: PegIntron®, Sylatron®

  • BiologicalIpilimumab

    IV infusion

    Also known as: Yervoy®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A)

    Participants in Part 1A were analyzed for DLTs. DLTs included all adverse experiences that were clearly not related to disease progression or intercurrent illness if judged by the investigator to be possibly, probably, or definitely related to study intervention. Reported adverse experiences used the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.0. DLTs were analyzed and reported separately for protocol specified clinical indications of metastatic melanoma (MEL) and renal cell carcinoma (RCC) in Part 1A: Part 1A Pembrolizumab + IPI 1mg/kg (MEL), Part 1A Pembrolizumab + IPI 1 mg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (MEL), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 2 µg/kg (RCC). Per protocol, DLT outcome analysis did not include Parts 1B and 1C.

    Time frame: Up to ~6 Weeks

  2. Percentage of Participants Experiencing Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0.The number of participants who experienced at least one AE was reported.

    Time frame: Up to ~84 months

  3. Percentage of Participants Discontinuing Study Drug Due to AEs

    An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the CTCAE Version 4.0. The percentage of participants who discontinued study treatment due to an AE was reported.

    Time frame: Up to ~24 months

  4. Percentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C)

    AEOSIs consist of immune-mediated events, infusion reactions and depression. Events include Pneumonitis, Colitis, Hepatitis, Nephritis, Adrenal Insufficiency, Hypophysitis, Hyperthyroidism, Hypothyroidism, Thyroiditis, Type 1 Diabetes Mellitus, Skin Disorders, Uveitis, Pancreatitis, Myositis, Guillain-Barre Syndrome, Myocarditis, Encephalitis, Sarcoidosis, Infusion Reactions, Myasthenic Syndrome, Myelitis, Vasculitis, and Cholangitis Sclerosing. Per protocol Part 1B and Part 1C are reported. Part 1A was not included in the AEOIs outcome analysis, per protocol.

    Time frame: Up to ~84 months

  5. Percentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C)

    Participants in Part 1C who experienced grade 3-5 drug-related AEs (DRAEs) using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Parts 1A and 1B was a secondary outcome analysis, per protocol and reported later in the record.

    Time frame: Up to ~84 months

  6. Objective Response Rate (ORR) (Part 1C)

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1C was planned and conducted as a pre-specified primary outcome analysis. ORR in Part 1B was planned and conducted as a protocol-specified secondary outcome analysis and has been reported later in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  7. Progression-free Survival (PFS) (Part 2)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was to be assessed by independent central review per RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure could not be reported.

    Time frame: Up to ~84 months

Secondary outcomes

  1. Objective Response Rate (ORR) (Part 1B)

    ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1B was planned and conducted as a pre-specified secondary outcome analysis. ORR in Part 1C was planned and conducted as a protocol-specified primary outcome analysis and has been reported earlier in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  2. ORR by Programmed-death Receptor-ligand 1 (PD-L1) Status Using RECIST 1.1 (Parts 1B and 1C)

    ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants that experienced a CR or PR by PD-L1 status is presented. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. ORR for participants in Parts 1B and 1C with measurable disease at baseline based on central independent review, who had ORR data available for PD-L1+ and PD-L1- participants are presented. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  3. Percentage of Participants With an Ordinal Response, Estimated by a Best Overall Response of VGPR or MPR (Parts 1B and 1C)

    Ordinal response, per RECIST 1.1 included the best overall responses of Very Good Partial Response (\[VGPR\]\>60% tumor reduction) as well as Moderate Partial Response (\[MPR\]\>30%- ≤60% tumor reduction). The percentage of participants in Part 1B and 1C who experienced a MPR or VGPR (based on the degree of tumor shrinkage) in participants with advanced melanoma is presented. Outcome analysis of ordinal response in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  4. Duration of Response (DOR) (Parts 1B and 1C)

    DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on central imaging review with confirmation. The DOR as assessed using RECIST 1.1 for participants with measurable disease at baseline based on central independent review in Parts 1B and 1C who experienced a confirmed CR or PR with DOR data available is presented. Outcome analysis of DOR in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  5. Progression-free Survival (PFS) (Parts 1B and 1C)

    PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by independent central review per RECIST 1.1 for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  6. Overall Survival (OS) (Parts 1B and 1C)

    OS was defined as the time from randomization to death due to any cause. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  7. PFS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)

    PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. PFS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  8. OS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)

    OS was defined as the time from randomization to death due to any cause. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.

    Time frame: Up to ~84 months

  9. Percentage of Participants Experiencing Grade 3-5 DRAEs (Parts 1A and 1B)

    Participants in Parts 1A and 1B who experienced DRAEs using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Part 1C was a primary outcome analysis, per protocol and reported earlier in the record.

    Time frame: Up to ~84 months

  10. ORR (Part 2)

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure was not reported.

    Time frame: Up to ~84 months

07

Results

Posted May 18, 2022

Participant flow

Participant flow — Overall Study
MilestonePart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Started231431535151
Treated221431535151
Completed000000
Not completed231431535151
Withdrew: Adverse event100010
Withdrew: Clinical progression400512
Withdrew: Excluded medication1001121
Withdrew: Progressive disease13103511712
Withdrew: Follow up ended by sponsor220702626
Withdrew: Withdrawal by subject020811
Withdrew: Status not recorded100010
Withdrew: Death000725
Withdrew: Lost to follow-up000100
Withdrew: Physician decision000004
Withdrew: Screen failure100000

Outcome measures

PrimaryPercentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A)

Participants in Part 1A were analyzed for DLTs. DLTs included all adverse experiences that were clearly not related to disease progression or intercurrent illness if judged by the investigator to be possibly, probably, or definitely related to study intervention. Reported adverse experiences used the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.0. DLTs were analyzed and reported separately for protocol specified clinical indications of metastatic melanoma (MEL) and renal cell carcinoma (RCC) in Part 1A: Part 1A Pembrolizumab + IPI 1mg/kg (MEL), Part 1A Pembrolizumab + IPI 1 mg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (MEL), Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (RCC), Part 1A Pembrolizumab + PEG-IFN 2 µg/kg (RCC). Per protocol, DLT outcome analysis did not include Parts 1B and 1C.

Time frame:
Up to ~6 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kg (MEL)Part 1A Pembrolizumab + IPI 1 mg/kg (RCC)Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (MEL)Part 1A Pembrolizumab + PEG-IFN 1 µg/kg (RCC)Part 1A Pembrolizumab + PEG-IFN 2 µg/kg (RCC)Part 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Percentage of Participants With Dose-limiting Toxicities (DLTs) (Part 1A)36.4 (20.6 to 54.5)25 (10.2 to 45.4)20 (5.1 to 44.8)0.0 (0.0 to 14.9)66.7 (36.5 to 89.4)———
PrimaryPercentage of Participants Experiencing Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the Common Terminology for Adverse Events (CTCAE) Version 4.0.The number of participants who experienced at least one AE was reported.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing Adverse Events (AEs)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Percentage of Participants Experiencing Adverse Events (AEs)100.0100.0100.099.3100.0100.0
PrimaryPercentage of Participants Discontinuing Study Drug Due to AEs

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. Reported adverse experiences used the CTCAE Version 4.0. The percentage of participants who discontinued study treatment due to an AE was reported.

Time frame:
Up to ~24 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing Study Drug Due to AEs
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Percentage of Participants Discontinuing Study Drug Due to AEs40.950.066.737.319.637.3
PrimaryPercentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C)

AEOSIs consist of immune-mediated events, infusion reactions and depression. Events include Pneumonitis, Colitis, Hepatitis, Nephritis, Adrenal Insufficiency, Hypophysitis, Hyperthyroidism, Hypothyroidism, Thyroiditis, Type 1 Diabetes Mellitus, Skin Disorders, Uveitis, Pancreatitis, Myositis, Guillain-Barre Syndrome, Myocarditis, Encephalitis, Sarcoidosis, Infusion Reactions, Myasthenic Syndrome, Myelitis, Vasculitis, and Cholangitis Sclerosing. Per protocol Part 1B and Part 1C are reported. Part 1A was not included in the AEOIs outcome analysis, per protocol.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Percentage of Participants Experiencing Adverse Events of Special Interest (AEOSIs) (Parts 1B and 1C)———60.845.156.9
PrimaryPercentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C)

Participants in Part 1C who experienced grade 3-5 drug-related AEs (DRAEs) using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Parts 1A and 1B was a secondary outcome analysis, per protocol and reported later in the record.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Percentage of Participants Experiencing Grade 3-5 Drug-related AEs (Part 1C)————27.543.1
PrimaryObjective Response Rate (ORR) (Part 1C)

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1C was planned and conducted as a pre-specified primary outcome analysis. ORR in Part 1B was planned and conducted as a protocol-specified secondary outcome analysis and has been reported later in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) (Part 1C)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Objective Response Rate (ORR) (Part 1C)————69.6 (54.2 to 82.3)76.7 (61.4 to 88.2)
PrimaryProgression-free Survival (PFS) (Part 2)

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was to be assessed by independent central review per RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure could not be reported.

Time frame:
Up to ~84 months

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR) (Part 1B)

ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Per protocol, ORR in Part 1B was planned and conducted as a pre-specified secondary outcome analysis. ORR in Part 1C was planned and conducted as a protocol-specified primary outcome analysis and has been reported earlier in the record. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) (Part 1B)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Objective Response Rate (ORR) (Part 1B)———65.8 (57.5 to 73.4)——
SecondaryORR by Programmed-death Receptor-ligand 1 (PD-L1) Status Using RECIST 1.1 (Parts 1B and 1C)

ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of participants that experienced a CR or PR by PD-L1 status is presented. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. ORR for participants in Parts 1B and 1C with measurable disease at baseline based on central independent review, who had ORR data available for PD-L1+ and PD-L1- participants are presented. Outcome analysis of ORR in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
ORR by Programmed-death Receptor-ligand 1 (PD-L1) Status Using RECIST 1.1 (Parts 1B and 1C)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
PD-L1 Positive———67.8 (58.7 to 76.0)75.0 (55.1 to 89.3)85.2 (66.3 to 95.8)
PD-L1 Negative———52.2 (30.6 to 73.2)53.8 (25.1 to 80.8)63.6 (30.8 to 89.1)
SecondaryPercentage of Participants With an Ordinal Response, Estimated by a Best Overall Response of VGPR or MPR (Parts 1B and 1C)

Ordinal response, per RECIST 1.1 included the best overall responses of Very Good Partial Response (\[VGPR\]\>60% tumor reduction) as well as Moderate Partial Response (\[MPR\]\>30%- ≤60% tumor reduction). The percentage of participants in Part 1B and 1C who experienced a MPR or VGPR (based on the degree of tumor shrinkage) in participants with advanced melanoma is presented. Outcome analysis of ordinal response in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Ordinal Response, Estimated by a Best Overall Response of VGPR or MPR (Parts 1B and 1C)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
MPR———6.2 (2.9 to 11.4)8.7 (2.4 to 20.8)23.3 (11.8 to 38.6)
VGPR———24.0 (17.3 to 31.7)28.3 (16.0 to 43.5)20.9 (10.0 to 36.0)
SecondaryDuration of Response (DOR) (Parts 1B and 1C)

DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on central imaging review with confirmation. The DOR as assessed using RECIST 1.1 for participants with measurable disease at baseline based on central independent review in Parts 1B and 1C who experienced a confirmed CR or PR with DOR data available is presented. Outcome analysis of DOR in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Median · Months
Duration of Response (DOR) (Parts 1B and 1C)
MonthsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Duration of Response (DOR) (Parts 1B and 1C)———NA (NA to NA)NA (NA to NA)NA (3.8 to NA)
SecondaryProgression-free Survival (PFS) (Parts 1B and 1C)

PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by independent central review per RECIST 1.1 for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Median · Months
Progression-free Survival (PFS) (Parts 1B and 1C)
MonthsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab+ IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Progression-free Survival (PFS) (Parts 1B and 1C)———NA (36.4 to NA)NA (14.1 to NA)NA (31.9 to NA)
SecondaryOverall Survival (OS) (Parts 1B and 1C)

OS was defined as the time from randomization to death due to any cause. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Median · Months
Overall Survival (OS) (Parts 1B and 1C)
MonthsPart 1A Pembrolizumab + IPI 1mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Overall Survival (OS) (Parts 1B and 1C)———NA (NA to NA)NA (NA to NA)NA (39.6 to NA)
SecondaryPFS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)

PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. PFS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had PFS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of PFS in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Median · Months
PFS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)
MonthsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
PD-L1 Positive———NA (41.6 to NA)NA (NA to NA)NA (35.7 to NA)
PD-L1 Negative———20.7 (2.8 to NA)23.1 (1.4 to NA)13.8 (1.4 to NA)
SecondaryOS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)

OS was defined as the time from randomization to death due to any cause. PD-L1 positivity was defined as ≥1% staining in tumor and inflammatory cells, while PD-L1 negativity is defined as \<1% staining. OS for all participants who received at least one dose of study treatment in Part 1B and all randomized participants in Part 1C, who had OS data available for PD-L1+ and PD-L1- participants is presented. Outcome analysis of OS in Part 1A was not planned or conducted in this study, per protocol.

Time frame:
Up to ~84 months
Reported as:
Median · Months
OS by PD-L1 Status Using RECIST 1.1 (Parts 1B and 1C)
MonthsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
PD-L1 Positive———NA (NA to NA)NA (NA to NA)NA (NA to NA)
PD-L1 Negative———NA (14.1 to NA)32.8 (12.9 to NA)NA (7.6 to NA)
SecondaryPercentage of Participants Experiencing Grade 3-5 DRAEs (Parts 1A and 1B)

Participants in Parts 1A and 1B who experienced DRAEs using CTCAE Version 4.0 are presented. Grade 3-5 DRAEs for Part 1C was a primary outcome analysis, per protocol and reported earlier in the record.

Time frame:
Up to ~84 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing Grade 3-5 DRAEs (Parts 1A and 1B)
Percentage of ParticipantsPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
Percentage of Participants Experiencing Grade 3-5 DRAEs (Parts 1A and 1B)90.971.466.770.6——
SecondaryORR (Part 2)

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Part 2 of the study was not conducted, based on protocol specified criteria and this Part 2 specific outcome measure was not reported.

Time frame:
Up to ~84 months

No measurements were reported for this outcome.

Adverse events

Collected over Up to approximately 84 months (through database cutoff date of 01-April-2021).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1A Pembrolizumab + IPI 1 mg/kg16/23 (69.6%)9/22 (40.9%)22/22 (100%)
Part 1A Pembrolizumab + PEG-IFN 1 µg/kg10/14 (71.4%)9/14 (64.3%)14/14 (100%)
Part 1A Pembrolizumab + PEG-IFN 2 µg/kg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part 1B Pembrolizumab + IPI 1 mg/kg51/153 (33.3%)78/153 (51%)152/153 (99.3%)
Part 1C Pembrolizumab + IPI 50 mg14/51 (27.5%)26/51 (51%)51/51 (100%)
Part 1C Pembrolizumab + IPI 100 mg17/51 (33.3%)25/51 (49%)51/51 (100%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
DepressionPsychiatric disorders0/221/141/31/1530/510/51
Suicide attemptPsychiatric disorders0/220/141/30/1530/510/51
PneumonitisRespiratory, thoracic and mediastinal disorders1/221/141/34/1531/512/51
ColitisGastrointestinal disorders3/220/140/36/1532/512/51
Atrial fibrillationCardiac disorders0/221/140/33/1530/510/51
Autoimmune thyroiditisEndocrine disorders0/221/140/30/1530/510/51
DiarrhoeaGastrointestinal disorders0/221/140/32/1530/510/51
NauseaGastrointestinal disorders0/221/140/30/1530/511/51
VomitingGastrointestinal disorders0/221/140/30/1530/510/51
PyrexiaGeneral disorders0/221/140/31/1531/511/51
Most frequent other events
Showing 10 of 206
Most frequent other events
EventPart 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + PEG-IFN 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mg
FatigueGeneral disorders9/2211/143/389/15331/5134/51
DiarrhoeaGastrointestinal disorders6/225/142/360/15323/5124/51
ChillsGeneral disorders2/225/142/311/1536/510/51
PyrexiaGeneral disorders5/225/142/320/1537/513/51
Alanine aminotransferase increasedInvestigations5/223/142/324/15310/516/51
Aspartate aminotransferase increasedInvestigations4/224/142/320/15310/517/51
DepressionPsychiatric disorders1/221/142/36/1530/512/51
CoughRespiratory, thoracic and mediastinal disorders8/229/142/338/15317/5111/51
PruritusSkin and subcutaneous tissue disorders3/225/142/371/15319/5130/51
RashSkin and subcutaneous tissue disorders4/225/142/373/15327/5124/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mgTotal
Mean59.4 ± 12.360.3 ± 10.461.7 ± 18.559.9 ± 12.560.8 ± 12.962.8 ± 1160.5 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Part 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mgTotal
Female105052131898
Male13931013833197
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mgTotal
Hispanic or Latino1001204
Not Hispanic or Latino21921424145260
Unknown or Not Reported151108631
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1A Pembrolizumab + IPI 1 mg/kgPart 1A Pembrolizumab + Pegylated Interferon Alfa-2b (PEG-IFN) 1 µg/kgPart 1A Pembrolizumab + PEG-IFN 2 µg/kgPart 1B Pembrolizumab + IPI 1 mg/kgPart 1C Pembrolizumab + IPI 50 mgPart 1C Pembrolizumab + IPI 100 mgTotal
American Indian or Alaska Native0000000
Asian2001115
Native Hawaiian or Other Pacific Islander0000000
Black or African American0110002
White191311504246271
More than one race0002002
Unknown or Not Reported20108415
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17. PubMed 28729151 ↗
  • Carlino MS, Menzies AM, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Homet Moreno B, Long GV. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 Oct 1;26(19):5086-5091. doi: 10.1158/1078-0432.CCR-20-0177. Epub 2020 Jun 30. PubMed 32605909 ↗
  • Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 Apr 15;24(8):1805-1815. doi: 10.1158/1078-0432.CCR-17-3436. Epub 2018 Jan 22. PubMed 29358500 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Apr 2021, 84 months.

Results were first posted in May 2022, 1 year 1 month after primary completion.

Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 84 months is above that.

Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2014
First posted
Mar 18, 2014
StartActual
Mar 17, 2014
Primary completionActual
Apr 1, 2021
CompletionActual
Apr 1, 2021
Results first posted
May 18, 2022
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02089685
Responsible party
Sponsor
First posted
Mar 18, 2014
Start date
Mar 17, 2014
Primary completion
Apr 1, 2021
Completion
Apr 1, 2021
Results posted
May 18, 2022
Last update
Sep 13, 2022

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Peginterferon alfa-2b · Ipilimumab

Start the discussion